[Glybenclamide (HB 419): a new oral antidiabetic agent of the sulfonylurea group].
D000328:Adult; D000367:Age Factors; D000368:Aged; D001645:Biguanides / Q000627:therapeutic use; D001786:Blood Glucose; D003920:Diabetes Mellitus / Q000188:drug therapy; D004357:Drug Synergism; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use; D000078790:Insulin Secretion; D008297:Male; D008875:Middle Aged; D013449:Sulfonamides
D001645:Biguanides; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D013449:Sulfonamides
Glybenclamid (HB 419): ein neues orales Antidiabetikum der Sulfonylharnstoff-Reihe.